TUESDAY, SEPTEMBER 27, 2016

VBI provides update on hepatitis C vaccine research at conference

VBI Vaccines updates industry representatives and leaders on its hepatits C vaccine research this week at the World Vaccine Congress Asia in Singapore.. | Courtesy of hepatitiscnewdrugresearch.com

VBI Vaccines recently presented the latest data about its eVLP platform being used in creating a new hepatitis C vaccine candidate at the World Vaccine Congress Asia, held Wednesday and Thursday at the Suntec Singapore Convention & Exhibition Centre in Singapore.

The new hepatitis C vaccine candidate uses the company’s eVLP vaccine platform to create enveloped (“e”) virus-like particle (“VLP”) vaccines. These eVLPs are now a novel class of synthetic vaccines that can be engineered to be very similar to a typical virus structure. This structure, which is commonly found in nature, enables eVLPs to provoke a stronger response from the immune system than the regular recombinant target protein.

The presentation, titled "Enveloped Virus-Like Particles: Third-Generation VLPs for the Development of Broadly Neutralizing Hepatitis C Vaccine, was presented by Jeff Baxter, president and CEO of VBI Vaccines.

"VBI has previously demonstrated strong cross-reactive neutralizing antibody responses against multiple genotypes of (hepatitis C virus) in monkeys," Baxter said. "Based on this data, we believe our HCV vaccine candidate has the potential to be a promising and safe component of HCV treatment regimens, especially in areas where the transmission of Hepatitis C has not yet been adequately addressed by the existing field of approved and available drugs."

Organizations in this story

VBI Vaccines Inc 222 Third St Cambridge, MA 02142

Get notified the next time we write about VBI Vaccines Inc!